LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...
Another mixed quarter in Q3 FY'22 for AngioDynamics, despite strengths in its international markets. Management revised guidance higher, but this may widen the operating loss as well, in my view.
Good morning, and welcome to the AngioDynamics Fiscal Year 2023 Third Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback